Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
05 mars 2024 08h00 HE
|
Nuvectis Pharma, Inc.
NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the FDANXP800...
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
09 févr. 2024 08h32 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
09 févr. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
18 déc. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by...
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
08 nov. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid...
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
24 oct. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
25 sept. 2023 19h30 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
21 sept. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
12 sept. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...